vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and SunOpta Inc. (STKL). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $205.4M, roughly 1.4× SunOpta Inc.). SunOpta Inc. runs the higher net margin — 0.4% vs -45.7%, a 46.1% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 16.6%). SunOpta Inc. produced more free cash flow last quarter ($12.1M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 7.4%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
SunOpta, Inc. is a multi-national food and mineral company headquartered in Eden Prairie, Minnesota and founded in 1973 in Canada.
GH vs STKL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $205.4M |
| Net Profit | $-128.5M | $816.0K |
| Gross Margin | 64.6% | 12.4% |
| Operating Margin | -43.0% | 3.3% |
| Net Margin | -45.7% | 0.4% |
| Revenue YoY | 39.4% | 16.6% |
| Net Profit YoY | -15.8% | 113.1% |
| EPS (diluted) | $-1.01 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | — | ||
| Q3 25 | $265.2M | $205.4M | ||
| Q2 25 | $232.1M | $191.5M | ||
| Q1 25 | $203.5M | $201.6M | ||
| Q4 24 | $201.8M | $193.9M | ||
| Q3 24 | $191.5M | $175.9M | ||
| Q2 24 | $177.2M | $169.5M | ||
| Q1 24 | $168.5M | $184.4M |
| Q4 25 | $-128.5M | — | ||
| Q3 25 | $-92.7M | $816.0K | ||
| Q2 25 | $-99.9M | $4.4M | ||
| Q1 25 | $-95.2M | $4.8M | ||
| Q4 24 | $-111.0M | $-8.7M | ||
| Q3 24 | $-107.8M | $-6.2M | ||
| Q2 24 | $-102.6M | $-5.3M | ||
| Q1 24 | $-115.0M | $2.9M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | 12.4% | ||
| Q2 25 | 65.0% | 14.8% | ||
| Q1 25 | 63.3% | 15.0% | ||
| Q4 24 | 61.6% | 10.9% | ||
| Q3 24 | 61.1% | 13.0% | ||
| Q2 24 | 59.1% | 12.5% | ||
| Q1 24 | 61.2% | 16.8% |
| Q4 25 | -43.0% | — | ||
| Q3 25 | -37.3% | 3.3% | ||
| Q2 25 | -45.9% | 5.5% | ||
| Q1 25 | -54.6% | 5.2% | ||
| Q4 24 | -62.4% | 1.4% | ||
| Q3 24 | -61.3% | 0.5% | ||
| Q2 24 | -56.8% | 1.2% | ||
| Q1 24 | -59.2% | 5.5% |
| Q4 25 | -45.7% | — | ||
| Q3 25 | -35.0% | 0.4% | ||
| Q2 25 | -43.0% | 2.3% | ||
| Q1 25 | -46.8% | 2.4% | ||
| Q4 24 | -55.0% | -4.5% | ||
| Q3 24 | -56.3% | -3.5% | ||
| Q2 24 | -57.9% | -3.1% | ||
| Q1 24 | -68.2% | 1.6% |
| Q4 25 | $-1.01 | — | ||
| Q3 25 | $-0.74 | $0.01 | ||
| Q2 25 | $-0.80 | $0.03 | ||
| Q1 25 | $-0.77 | $0.04 | ||
| Q4 24 | $-0.90 | $-0.08 | ||
| Q3 24 | $-0.88 | $-0.05 | ||
| Q2 24 | $-0.84 | $-0.04 | ||
| Q1 24 | $-0.94 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $2.2M |
| Total DebtLower is stronger | $1.5B | $250.8M |
| Stockholders' EquityBook value | $-99.3M | $162.8M |
| Total Assets | $2.0B | $694.1M |
| Debt / EquityLower = less leverage | — | 1.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | — | ||
| Q3 25 | $580.0M | $2.2M | ||
| Q2 25 | $629.1M | $2.2M | ||
| Q1 25 | $698.6M | $2.3M | ||
| Q4 24 | $525.5M | $1.6M | ||
| Q3 24 | $585.0M | $2.9M | ||
| Q2 24 | $933.7M | $3.2M | ||
| Q1 24 | $1.0B | $1.5M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | $250.8M | ||
| Q2 25 | $1.1B | $263.3M | ||
| Q1 25 | $1.1B | $260.6M | ||
| Q4 24 | $1.1B | $265.2M | ||
| Q3 24 | — | $289.9M | ||
| Q2 24 | — | $303.1M | ||
| Q1 24 | — | $258.8M |
| Q4 25 | $-99.3M | — | ||
| Q3 25 | $-354.5M | $162.8M | ||
| Q2 25 | $-305.5M | $159.8M | ||
| Q1 25 | $-250.8M | $154.8M | ||
| Q4 24 | $-139.6M | $148.6M | ||
| Q3 24 | $-60.1M | $155.0M | ||
| Q2 24 | $-1.6M | $158.8M | ||
| Q1 24 | $68.3M | $163.6M |
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.3B | $694.1M | ||
| Q2 25 | $1.3B | $704.9M | ||
| Q1 25 | $1.3B | $690.7M | ||
| Q4 24 | $1.5B | $668.5M | ||
| Q3 24 | $1.5B | $699.3M | ||
| Q2 24 | $1.6B | $704.7M | ||
| Q1 24 | $1.7B | $671.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.54× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.68× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | 1.91× | ||
| Q1 24 | — | 1.58× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $16.3M |
| Free Cash FlowOCF − Capex | $-54.2M | $12.1M |
| FCF MarginFCF / Revenue | -19.3% | 5.9% |
| Capex IntensityCapex / Revenue | 9.9% | 2.1% |
| Cash ConversionOCF / Net Profit | — | 20.03× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $36.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | — | ||
| Q3 25 | $-35.4M | $16.3M | ||
| Q2 25 | $-60.3M | $-4.5M | ||
| Q1 25 | $-62.7M | $22.3M | ||
| Q4 24 | $-64.5M | $33.1M | ||
| Q3 24 | $-51.1M | $17.2M | ||
| Q2 24 | $-94.0M | $-5.6M | ||
| Q1 24 | $-30.3M | $5.3M |
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | $12.1M | ||
| Q2 25 | $-65.9M | $-9.2M | ||
| Q1 25 | $-67.1M | $9.5M | ||
| Q4 24 | $-83.4M | $24.0M | ||
| Q3 24 | $-55.3M | $11.7M | ||
| Q2 24 | $-99.1M | $-15.3M | ||
| Q1 24 | $-37.2M | $-2.3M |
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | 5.9% | ||
| Q2 25 | -28.4% | -4.8% | ||
| Q1 25 | -33.0% | 4.7% | ||
| Q4 24 | -41.3% | 12.4% | ||
| Q3 24 | -28.9% | 6.6% | ||
| Q2 24 | -55.9% | -9.0% | ||
| Q1 24 | -22.1% | -1.2% |
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | 2.1% | ||
| Q2 25 | 2.4% | 2.5% | ||
| Q1 25 | 2.2% | 6.3% | ||
| Q4 24 | 9.4% | 4.7% | ||
| Q3 24 | 2.2% | 3.2% | ||
| Q2 24 | 2.9% | 5.7% | ||
| Q1 24 | 4.1% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | 20.03× | ||
| Q2 25 | — | -1.03× | ||
| Q1 25 | — | 4.63× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
STKL
| Beverages And Broths | $161.4M | 79% |
| Fruit Snacks | $40.9M | 20% |
| Ingredients | $3.1M | 2% |
